Mi Lin
Research Subjects
Mi Lin has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Chang-Ming Huang
Fujian Medical University Union Hospital
25 shared publications - Jian-Xian Lin
Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
25 shared publications - Ping Li
Fujian Medical University Union Hospital
25 shared publications - Qi-Yue Chen
Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
25 shared publications - Qing Zhong
Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
25 shared publications - Ru-Hong Tu
Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
25 shared publications
Latest Publications
- 22 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
Gastric Mixed Neuroendocrine-Non-neuroendocrine Neoplasms Develop from POU2F3+ Multipotent Progenitors
Gastric mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) are aggressive malignancies that exhibit complex cellular heterogeneity driven by the dual lineages. The dismal patient survival rates highlight the need to elucidate the cellular origin of gastric MiNENs and the key regulatory mechanisms to develop improved treatment strategies. Here, we identified a gastric POU2F3+epithelial population as a potential cell of origin for gastric MiNENs. Lineage tracing and single-cell RNA sequencing further identified that POU2F3+ cells include three distinct subpopulations with divergent differentiation trajectories: progenitor cells (SOX2+SOX9+), tuft cells (POU2F3+DCLK1+), and neuroendocrine cells (SYP+CHGA+). Combined Rb1/Trp53 deletion and MYC overexpression in POU2F3+ epithelial cells (Pou2f3-CreERT; Rb1fl/fl; Trp53fl/fl; LSL-MycT58A) led to the rapid development of gastric MiNENs containing both neuroendocrine and non-neuroendocrine lesions, recapitulating human gastric MiNENs pathology. Transcription factor activity analysis and spatial transcriptomics revealed SOX2 and SOX9 as critical regulators driving subpopulation specification, with SOX2 and SOX9 being enriched in dysplasia and adenocarcinoma, respectively. Bulk RNA sequencing further showed increased expression of CXCL5 in gastric MiNENs, and inhibition of CXCL5 reduced the growth of tumor organoids and xenografts in mouse models. Together these findings offer a physiologically relevant model for studying gastric MiNENs and identify CXCL5 as a potential therapeutic target for this heterogeneous cancer.
- 22 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
Gastric Mixed Neuroendocrine-Non-neuroendocrine Neoplasms Develop from POU2F3+ Multipotent Progenitors
Gastric mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) are aggressive malignancies that exhibit complex cellular heterogeneity driven by the dual lineages. The dismal patient survival rates highlight the need to elucidate the cellular origin of gastric MiNENs and the key regulatory mechanisms to develop improved treatment strategies. Here, we identified a gastric POU2F3+epithelial population as a potential cell of origin for gastric MiNENs. Lineage tracing and single-cell RNA sequencing further identified that POU2F3+ cells include three distinct subpopulations with divergent differentiation trajectories: progenitor cells (SOX2+SOX9+), tuft cells (POU2F3+DCLK1+), and neuroendocrine cells (SYP+CHGA+). Combined Rb1/Trp53 deletion and MYC overexpression in POU2F3+ epithelial cells (Pou2f3-CreERT; Rb1fl/fl; Trp53fl/fl; LSL-MycT58A) led to the rapid development of gastric MiNENs containing both neuroendocrine and non-neuroendocrine lesions, recapitulating human gastric MiNENs pathology. Transcription factor activity analysis and spatial transcriptomics revealed SOX2 and SOX9 as critical regulators driving subpopulation specification, with SOX2 and SOX9 being enriched in dysplasia and adenocarcinoma, respectively. Bulk RNA sequencing further showed increased expression of CXCL5 in gastric MiNENs, and inhibition of CXCL5 reduced the growth of tumor organoids and xenografts in mouse models. Together these findings offer a physiologically relevant model for studying gastric MiNENs and identify CXCL5 as a potential therapeutic target for this heterogeneous cancer.
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
DEGs in whole transcriptome sequencing between HGC-27 cells treated with 5-HT and control.
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
DEGs in whole transcriptome sequencing between HGC-27 cells treated with 5-HT and control.
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
Supplementary Figure 9. HTR2B overexpression correlates with poor prognosis. (A) Kaplan–Meier survival analysis comparing disease-specific survival rates based on low vs. high expression of HTR2B mRNA in TCGA cohorts (n = 370). (B) Forest plot showing the hazard ratio for 5-year overall survival (OS) in our local dataset. (C) Kaplan–Meier survival analysis comparing overall survival in patients stratified by high versus low IHC scores for HTR2B, further classified by TNM stage of gastric cancer in the local cohort (n = 188). (D) Representative IHC staining of HIF1α in human gastric tumors. (E and F) Kaplan–Meier survival analysis comparing overall survival (E) and disease-specific survival (F) rates based on low vs. high expression of HIF1α mRNA in TCGA cohorts (n = 370).
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
Supplementary Figure 9. HTR2B overexpression correlates with poor prognosis. (A) Kaplan–Meier survival analysis comparing disease-specific survival rates based on low vs. high expression of HTR2B mRNA in TCGA cohorts (n = 370). (B) Forest plot showing the hazard ratio for 5-year overall survival (OS) in our local dataset. (C) Kaplan–Meier survival analysis comparing overall survival in patients stratified by high versus low IHC scores for HTR2B, further classified by TNM stage of gastric cancer in the local cohort (n = 188). (D) Representative IHC staining of HIF1α in human gastric tumors. (E and F) Kaplan–Meier survival analysis comparing overall survival (E) and disease-specific survival (F) rates based on low vs. high expression of HIF1α mRNA in TCGA cohorts (n = 370).
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
Supplementary Data 1-Whole-transcriptome sequencing of 49 human gastric tumor tissues and adjacent non-tumor tissues in our center
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
Supplementary Data 1-Whole-transcriptome sequencing of 49 human gastric tumor tissues and adjacent non-tumor tissues in our center
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
Supplementary Figure 8. ABCD1 modulates lipid metabolism to attenuate lipid peroxidation. (A-C) AGS and HGC-27 cells from both si-control and si-ABCD1 groups were treated with vehicle or 5-HT (10 μM) for 48 h. Representative confocal images show fluorescence staining in AGS (A) and HGC-27 cells (C) using C11-BODIPY dye. (B) The rate of intracellular lipid ROS in AGS cells was measured by C11-BODIPY fluorescence (n = 3). **p < 0.01; ns, not significant. (D) Expression levels of HIF1α, ABCD1, ACSl4, and GPX4 were evaluated by immunoblot analysis in AGS and HGC-27 cells after 24h treatment with vehicle or 5-HT (10 μM) under normoxic (20% O2) or hypoxic (1% O2) conditions. (E) Representative IHC images showing HIF1α expression in subcutaneous xenograft tumor tissues from SB204741-treated vs. control groups and sh-HTR2B vs. sh-vector groups. (F) After treatment with PP2 (50 nM), AGS and HGC-27 cells were cultured with 5-HT (10 μM) for another 24 h. Levels of Fyn, HIF1α, ABCD1, and phosphorylated and total forms of Akt and mTOR were assessed by immunoblot. (G and H) Representative IHC images of p85 (G) and Fyn (H) from SB204741-treated vs. control or sh-HTR2B vs. sh-vector groups in subcutaneous xenograft tumor tissues.
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
Supplementary Figure 8. ABCD1 modulates lipid metabolism to attenuate lipid peroxidation. (A-C) AGS and HGC-27 cells from both si-control and si-ABCD1 groups were treated with vehicle or 5-HT (10 μM) for 48 h. Representative confocal images show fluorescence staining in AGS (A) and HGC-27 cells (C) using C11-BODIPY dye. (B) The rate of intracellular lipid ROS in AGS cells was measured by C11-BODIPY fluorescence (n = 3). **p < 0.01; ns, not significant. (D) Expression levels of HIF1α, ABCD1, ACSl4, and GPX4 were evaluated by immunoblot analysis in AGS and HGC-27 cells after 24h treatment with vehicle or 5-HT (10 μM) under normoxic (20% O2) or hypoxic (1% O2) conditions. (E) Representative IHC images showing HIF1α expression in subcutaneous xenograft tumor tissues from SB204741-treated vs. control groups and sh-HTR2B vs. sh-vector groups. (F) After treatment with PP2 (50 nM), AGS and HGC-27 cells were cultured with 5-HT (10 μM) for another 24 h. Levels of Fyn, HIF1α, ABCD1, and phosphorylated and total forms of Akt and mTOR were assessed by immunoblot. (G and H) Representative IHC images of p85 (G) and Fyn (H) from SB204741-treated vs. control or sh-HTR2B vs. sh-vector groups in subcutaneous xenograft tumor tissues.
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
Supplementary Figure 7. Nuclear translocation of HIF1α upon 5-HT stimulation. (A) Volcano plots of significant DEGs show downregulation of SIRT6 and EGLN2, genes known to negatively regulate HIF1α transcription. These are based on the DEG profiles of HGC-27 cells treated with vehicle versus those treated with 5-HT at 10 μM (n = 3). (B) The proteins Fyn, HIF1α, ABCD1, ACSL4, GPX4, phosphorylated and total Akt, and mTOR were measured by immunoblot in both sh-vector and sh-HTR2B cells. (C and D) Immunofluorescence staining was performed to analyze the subcellular localization of HIF1α in HGC-27 (C) and AGS (D) cells, with or without 5-HT (10 μM) treatment for 24 h. (E-H) AGS and HGC-27 cells from both si-control and si-ABCD1 groups were treated with vehicle or 5-HT (10 μM) for 48 h. Representative confocal images show fluorescence staining in AGS (E) and HGC-27 cells (G) via DCFH-DA dye. Rates of intracellular ROS were measured by DCFH-DA fluorescence in AGS (F) and HGC-27 cells (H) at the indicated time points (n = 3). *p < 0.05, ***p < 0.001; ns, not significant.
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
Supplementary Figure 7. Nuclear translocation of HIF1α upon 5-HT stimulation. (A) Volcano plots of significant DEGs show downregulation of SIRT6 and EGLN2, genes known to negatively regulate HIF1α transcription. These are based on the DEG profiles of HGC-27 cells treated with vehicle versus those treated with 5-HT at 10 μM (n = 3). (B) The proteins Fyn, HIF1α, ABCD1, ACSL4, GPX4, phosphorylated and total Akt, and mTOR were measured by immunoblot in both sh-vector and sh-HTR2B cells. (C and D) Immunofluorescence staining was performed to analyze the subcellular localization of HIF1α in HGC-27 (C) and AGS (D) cells, with or without 5-HT (10 μM) treatment for 24 h. (E-H) AGS and HGC-27 cells from both si-control and si-ABCD1 groups were treated with vehicle or 5-HT (10 μM) for 48 h. Representative confocal images show fluorescence staining in AGS (E) and HGC-27 cells (G) via DCFH-DA dye. Rates of intracellular ROS were measured by DCFH-DA fluorescence in AGS (F) and HGC-27 cells (H) at the indicated time points (n = 3). *p < 0.05, ***p < 0.001; ns, not significant.
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
Clinicopathological characteristics of 188 patients with gastric cancer in Fujian Medical University Union Hospital (FJMUUH)
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
Clinicopathological characteristics of 188 patients with gastric cancer in Fujian Medical University Union Hospital (FJMUUH)
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
Supplementary Figure 2. HTR2B plays a protective role in gastric cells. (A and B) Cell viability of HGC-27 (A) and AGS (B) cells at different concentrations of 5-HT in the absence of serum for 24 h (n = 3). (C-H) Cell viability was measured in five gastric cell lines (AGS, HGC-27, BGC-823, MKN-45, and NCI-N87) and the non-malignant cell line (GES-1) in the presence of vehicle or 5-HT (10 μM) (n = 3). *p < 0.05, ** p < 0.01. (I) Cell viability of HGC-27 cells at different concentrations of α-Me-HTP (a specific agonist of HTR2B) and SB204741 (a selective HTR2B antagonist) in the absence of serum for 24 h (n = 3). *p < 0.05, **** p < 0.0001. (J) Representative confocal images showing fluorescence staining in AGS cells treated with vehicle, 5-HT (10 μM), α-Me-HTP (100 μM), or SB204741 (100 μM) for 48 h using the EdU-488 dye. (K) The efficiency of HTR2B knockdown by shRNA interference in AGS and HGC-27 cells was quantified using western blot analysis. (L) Viability of cells exposed to 10 μM 5-HT under standard culture conditions (10% (v/v) FBS) was assessed (n = 3). (M) Cell viability was evaluated in the presence of 100 μM SB204741 under standard culture conditions (10% (v/v) FBS) (n = 3).
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer
Supplementary Figure 2. HTR2B plays a protective role in gastric cells. (A and B) Cell viability of HGC-27 (A) and AGS (B) cells at different concentrations of 5-HT in the absence of serum for 24 h (n = 3). (C-H) Cell viability was measured in five gastric cell lines (AGS, HGC-27, BGC-823, MKN-45, and NCI-N87) and the non-malignant cell line (GES-1) in the presence of vehicle or 5-HT (10 μM) (n = 3). *p < 0.05, ** p < 0.01. (I) Cell viability of HGC-27 cells at different concentrations of α-Me-HTP (a specific agonist of HTR2B) and SB204741 (a selective HTR2B antagonist) in the absence of serum for 24 h (n = 3). *p < 0.05, **** p < 0.0001. (J) Representative confocal images showing fluorescence staining in AGS cells treated with vehicle, 5-HT (10 μM), α-Me-HTP (100 μM), or SB204741 (100 μM) for 48 h using the EdU-488 dye. (K) The efficiency of HTR2B knockdown by shRNA interference in AGS and HGC-27 cells was quantified using western blot analysis. (L) Viability of cells exposed to 10 μM 5-HT under standard culture conditions (10% (v/v) FBS) was assessed (n = 3). (M) Cell viability was evaluated in the presence of 100 μM SB204741 under standard culture conditions (10% (v/v) FBS) (n = 3).